Decipher, Polaris and Oncotype in prostate cancer – pro
It is now mentioend by NCCN, in the sense that the NCCN now recommends that physicians offer active surveillance to patients with favorable intermediate-risk prostate cancer (Gleason 3+4, PSA <10 ng/mL, low-volume disease) and that genomic testing may be considered for patients with low-risk and favorable intermediate-risk prostate cancer. There are 3 avialalbe tests that do that, Polaris, Decipher and OncotypeDx. Retrospective studies suggest that each test picks up an overlapping but a distinct sub-group at risk for recurrence. As such and since NCCN does not recommend tests by name, none of these tests are medically necessary.
NCCN, Prostate 2018
Source Reference: Wagner J, et al “Prostate cancer genomics: Comparing Decipher, Prolaris, and Oncotype DX Results” AUA 2018; Abstract PD06-09.